As I have noted in numerous posts on this site, since the initial outbreak of COVID-19 in March 2020, plaintiffs’ lawyers have filed a host of coronavirus-related securities class action lawsuits. As I also noted, the plaintiffs’ track record in these cases has been mixed at best, with a number of the cases being dismissed. In the latest example of the hurdles the plaintiffs are facing in these cases, a federal court has entered an order dismissing the COVID-19 related securities suit that was filed against the pharmaceutical company AstraZeneca relating to the company’s troubled efforts to develop a COVID-19 vaccine. A copy of the September 12, 2022 opinion in the case can be found here.
Continue Reading AstraZeneca COVID-19-Related Securities Suit Dismissed